^
    Back
    Association details:
    Biomarker:MYD88 L265P
    Cancer:Multiple Myeloma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) +
    bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cureus
    Title:

    Simultaneous Presentation of Waldenström's Macroglobulinemia and MYD88 Gene Mutation with Multiple Myeloma

    Published date:
    01/03/2019
    Excerpt:
    A subsequent bone marrow biopsy showed B-cell NHLs with plasmacytic differentiation and positive MYD88 L265P mutation...we started him on a new treatment with Revlimid, Velcade and dexamethasone, his M-protein concentration significantly improved (Figure ​3).
    Secondary therapy:
    dexamethasone
    DOI:
    10.7759/cureus.3822